β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study by Puymirat, E et al.
the bmj | BMJ 2016;354:i4801 | doi: 10.1136/bmj.i4801
RESEARCH
1
open access
For numbered affiliations see 
end of article.
Correspondence to: E Puymirat 
etienne.puymirat@egp.aphp.fr
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2016;354:i4801
http://dx.doi.org/10.1136/bmj.i4801
Accepted: 2 September 2016
β blockers and mortality after myocardial infarction in patients 
without heart failure: multicentre prospective cohort study
Etienne Puymirat,1,2,3 Elisabeth Riant,1,2,3 Nadia Aissoui,2,3,4 Angèle Soria,2,5,6,7 Gregory Ducrocq,2,8,9,10 
Pierre Coste,11,12 Yves Cottin,13,14 Jean François Aupetit,15 Eric Bonnefoy,16,17 Didier Blanchard,18 
Simon Cattan,19 Gabriel Steg,2,8,9,10 François Schiele,20,21 Jean Ferrières,22,23 Yves Juillière,24,25 
Tabassome Simon,2,26 Nicolas Danchin1,2,3 
ABSTRACT
ObjeCtive
To assess the association between early and 
prolonged β blocker treatment and mortality after 
acute myocardial infarction.
Design
Multicentre prospective cohort study.
setting
Nationwide French registry of Acute ST- and non-ST-
elevation Myocardial Infarction (FAST-MI) (at 223 
centres) at the end of 2005.
PartiCiPants
2679 consecutive patients with acute myocardial 
infarction and without heart failure or left ventricular 
dysfunction.
Main OutCOMe Measures
Mortality was assessed at 30 days in relation to early 
use of β blockers (≤48 hours of admission), at one year 
in relation to discharge prescription, and at five years 
in relation to one year use.
results
β blockers were used early in 77% (2050/2679) of 
patients, were prescribed at discharge in 80% 
(1783/2217), and were still being used in 89% 
(1230/1383) of those alive at one year. Thirty day 
mortality was lower in patients taking early β blockers 
(adjusted hazard ratio 0.46, 95% confidence interval 
0.26 to 0.82), whereas the hazard ratio for one year 
mortality associated with β blockers at discharge was 
0.77 (0.46 to 1.30). Persistence of β blockers at one 
year was not associated with lower five year mortality 
(hazard ratio 1.19, 0.65 to 2.18). In contrast, five year 
mortality was lower in patients continuing statins at 
one year (hazard ratio 0.42, 0.25 to 0.72) compared 
with those discontinuing statins. Propensity score and 
sensitivity analyses showed consistent results.
COnClusiOns
Early β blocker use was associated with reduced 30 
day mortality in patients with acute myocardial 
infarction, and discontinuation of β blockers at one 
year was not associated with higher five year 
mortality. These findings question the utility of 
prolonged β blocker treatment after acute myocardial 
infarction in patients without heart failure or left 
ventricular dysfunction.
trial registratiOn
Clinical trials NCT00673036.
Introduction
The benefit of β blockers is undisputed in patients with 
heart failure or left ventricular dysfunction in sinus 
rhythm and consistent in patients with ischaemic or 
non-ischaemic systolic heart failure.1 2  Most trials 
assessing the effect of β blockers after acute myocardial 
infarction were carried out several decades ago, at a 
time when reperfusion therapy was not used and when 
currently used secondary prevention drugs such as 
statins were not available.3  In the reperfusion era, the 
large Clopidogrel and Metoprolol in Myocardial Infarc-
tion Trial (COMMIT) had its primary endpoint at 28 
days; none of the patients had primary percutaneous 
coronary intervention, and 45% of the patients received 
no reperfusion therapy.4 Most patients with acute myo-
cardial infarction, however, including those with pre-
served left ventricular function, receive β blockers at 
discharge and continue their treatment for years after 
the acute episode.
The lack of recent evidence on the effect of β blockers 
has resulted in divergences between European and 
American guidelines,5-8  and the role of the long term 
use of β blockers after acute myocardial infarction in 
patients without heart failure and with adequate left 
ventricular function is controversial.9 The purpose of 
this study was to assess the associations of β blocker 
use and adherence to treatment with short term and 
long term mortality by using data from the nationwide 
French registry of Acute ST-elevation and non-ST-eleva-
tion Myocardial Infarction (FAST-MI) 2005. We assessed 
the relation between β blocker use and mortality at 
three time points: early use (within 48 hours of 
 admission) in relation to 30 day mortality, prescription 
of β blockers at discharge in relation to one year mortal-
ity, and persistent use of β blockers at one year in rela-
tion to five year mortality.
WhAT IS AlReAdy knoWn on ThIS TopIC
Most randomised controlled trials of β blockers after acute myocardial infarction were 
conducted before the era of reperfusion therapy and modern secondary prevention
Their usefulness in patients currently treated for acute myocardial infarction with 
preserved left ventricular function is debated, leading to divergences between 
European and American guidelines
WhAT ThIS STudy AddS
This analysis from a nationwide French registry shows a decrease over time in the 
association of β blocker treatment with survival in acute myocardial infarction 
patients without heart failure or left ventricular dysfunction
Early use of β blockers at the acute stage of myocardial infarction seems to be 
associated with a substantial decrease in 30 day mortality
Prolonged β blocker treatment beyond one year is unlikely to improve survival
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Methods
study design
The population and methods of the FAST-MI registry 
have been described in detail elsewhere.10 11 Briefly, the 
objective of the study was to collect comprehensive data 
on the management and outcome of consecutive 
patients admitted to intensive care units for definite 
acute myocardial infarction over a one month period in 
France, irrespective of the type of institution to which 
the patients were admitted (university hospitals, public 
hospitals, or private clinics, with or without on-site 
catheterisation facilities). Of the 374 centres that treated 
patients with acute myocardial infarction at that time, 
223 (60%) participated in the study.
All consecutive adult (≥18 years) patients admitted to 
the participating centres during a one month period 
beginning on 1 October 2005, with a one month exten-
sion for patients with diabetes, were included in the reg-
istry if they had elevated serum markers of myocardial 
necrosis higher than twice the upper limit of normal for 
creatine kinase, creatine kinase-MB, or elevated tro-
ponins; had symptoms compatible with acute myocar-
dial infarction and/or electrocardiographic changes on 
at least two contiguous leads with pathological Q waves 
and/or persisting ST elevation or depression greater 
than 0.1 mV; and consented to participate in the study. 
The time from the onset of symptoms to admission to the 
intensive care unit had to be less than 48 hours. Patients 
with iatrogenic myocardial infarction, defined as occur-
ring within 48 hours of a therapeutic procedure, and 
those in whom diagnosis of acute  myocardial infarction 
was invalidated in favour of another diagnosis were 
excluded from the survey. Patients were not involved in 
the registry organisation. The patients had to give their 
informed consent for participation in the study.
Data collection
Specially trained research technicians who visited each 
centre at least once a week prospectively recorded all data 
on computerised case record forms. Cardiovascular his-
tory, drug treatment at the time of admission, risk factors, 
and in-hospital clinical course, including maximal Killip 
class, as well as initial diagnostic and therapeutic man-
agement, were recorded for each patient. Discharge drugs, 
including type and dose of β blockers, were recorded. We 
considered doses at or above 50 mg/day for atenolol, 
100 mg/day for metoprolol, 200 mg/day for acebutolol, or 
5 mg/day for bisoprolol to be moderate to high doses.
Follow-up was centralised at the French Society of 
Cardiology, and dedicated research technicians con-
tacted both the physicians and the patients themselves 
or their families, after checking the patients’ vital status 
in municipal registers. Information on cardiovascular 
and non-cardiovascular hospital admissions and drug 
prescriptions during follow-up was sought; drug use 
was self reported by the patients and in many instances 
supported by copies of the medical prescription.
When the patients or their families or physicians 
reported events that had led to hospital admission, 
 hospital discharge letters and supportive documents 
were retrieved whenever possible. All events reported 
were reviewed by at least one member of a three mem-
ber critical events committee (ND, TS, and Pascal 
Guéret); the committee reviewed all cases that seemed 
debatable. Cause of death was assessed in the same way 
and  additionally cross linked with the national data-
base of causes of deaths. For the analysis presented 
here, we used the following classification: cardiovascu-
lar cause, non-cardiovascular cause, cause undeter-
mined; in addition, we categorised mode of death into 
sudden or non-sudden.
The rates of patients lost to follow-up for vital status 
were 0.3% at one year and 4.1% at five years. The 
 outcome variables used for this study were all cause 
mortality at 30 days, one year, and five years.
Populations studied
A first analysis focused on the association between early 
use of β blockers (within 48 hours of admission) and 30 
day mortality in patients without previous history of 
heart failure and without signs of heart failure on admis-
sion (Killip class I) (population 1; fig 1 ). We then anal-
ysed the relation between β blockers at discharge and 
one year mortality in the population without history of 
heart failure and with no sign of heart failure (Killip 
class I) throughout the hospital stay and without docu-
mentation of an ejection fraction of 40% or below before 
hospital discharge (using echocardiography, contrast 
left ventricular angiography, or radionuclide assess-
ment of left ventricular function) (population 2; fig 1 ). 
We did a third analysis in the subset of population 2 who 
had received β blockers at discharge and were alive at 
one year, to determine five year outcome according to 
persistence of β blockers at one year (population 3; fig 1).
Finally, we did an analysis of five year mortality accord-
ing to persistence of statin treatment at one year in 
With history of heart failure,
or admission Killip class >I (n=991)
Died in hospital, Killip >I, 
or LVEF ≤40% (n=462)
Prescription at one year unknown (n=400)
Population 1: patients (n=2679)
Population 3: prescription known at one year (n=1383)
Without β blockers:
(n=434, 20%)
With β blockers:
(n=1783, 80%)
Patients (n=3670)
Population 2: patients discharged alive, 
with no history of heart failure, Killip I during 
acute event, and LVEF not ≤40% (n=2217) 
Without β blockers: 
(n=153, 11%)
With β blockers:
(n=1230, 89%)
Fig 1 | Flowchart of populations from Fast-Mi studied at 
different time points. lveF=left ventricular ejection fraction
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 population 3 patients who were discharged taking 
statins. We used this analysis to determine whether its 
results would be concordant with those of the ran-
domised trials of statins after acute myocardial infarc-
tion, which, unlike β blocker trials, were conducted in the 
contemporary era of reperfusion therapy and invasive 
strategies for patients with acute coronary syndromes.
statistical analysis
All continuous variables are described as their mean val-
ues with standard deviation or as median and interquar-
tile range. All categorical variables are described using 
absolute and relative frequency distributions. Compari-
sons between groups used unpaired t tests or non-para-
metric Mann-Whitney tests for continuous variables and 
χ2 tests for discrete variables. We generated survival 
curves by using the Kaplan and Meier method and used 
log rank tests to compare them. Patients lost to follow-up 
were kept in the analyses and censored at the time they 
were last known to be alive. We used backwards Cox mul-
tivariable analyses for assessing the association between 
β blockers and mortality. We used a P value of 0.05 for 
inclusion and 0.10 for exclusion. We calculated the 
cumulative hazard functions for each covariate to assess 
proportionality and verified collinearity by calculating 
variance inflation factors.
We did several analyses using different sets of covari-
ates for the three populations studied. We selected 
covariates ad hoc, on the basis of their physiological 
relevance and potential to be associated with short term 
or long term mortality. A detailed description of the 
variables used is provided in appendix 1 of the supple-
mentary material.
In addition, we used non-parsimonious logistic regres-
sion analysis to calculate propensity scores for getting β 
blockers at each time point (first 48 hours, discharge, one 
year), leading to one propensity score for each popula-
tion. Within each population, we matched one patient 
not receiving β blockers with a given propensity score 
with one (populations 1 and 2) or three (population 3) 
patients receiving β blockers and having a similar pro-
pensity score, by using a greedy procedure based on the 
Mahalanobis distance within propensity score callipers 
set at a 0.2*sigma. A first propensity score was calculated 
in population 1, and two cohorts were matched with a 1:1 
ratio (502 patients each); a second propensity score was 
calculated in population 2, with a 1:1 matching procedure 
(383 patients each); finally, a third propensity score was 
calculated in population 3, with a 3:1 matching proce-
dure (95 patients who discontinued β blockers and 277 
with prolonged β blocker treatment). Model fits were sat-
isfactory: Hosmer-Lemeshow P value 0.41, C statistic 0.75 
for the model in population 1; Hosmer-Lemeshow P value 
0.83, C statistic 0.83 for population 2; and Hosmer-Leme-
show P value 0.45, C statistic 0.72 for population 3. We 
also used propensity score matching (3:1 matching) to 
compare patients with continued versus discontinued 
statin treatment at one year in the population who had 
received both statins and β blockers at discharge. Model 
fit for continuation of statins at one year: Hosmer-Leme-
show P value 0.63, C statistic 0.80.
We used the IBM-SPSS version 20.0 and NCSS 9 soft-
ware for all analyses. For all tests, we considered a P 
value of less than 0.05 (two sided) to be significant.
Patient involvement
No patients were involved in setting the research ques-
tion, nor were they involved in developing plans for 
recruitment, design, or implementation of the study. No 
patients were asked to advise on interpretation or writ-
ing up of results. Patients were contacted personally 
during follow-up, and we sent them a newsletter on the 
course of the study and its main findings.
Results
β blockers in first 48 hours and 30 day mortality
Of the 3670 patients included in the registry, 991 had a 
history of heart failure before the current episode or had 
Killip class II or higher at admission. Among the 2679 
patients included, 2050 (76.5%) were treated with β 
blockers during the first 48 hours after admission. 
Patients who were given β blockers were younger than 
those who were not, with a lower GRACE risk score and 
less comorbidity (table 1). After propensity score match-
ing, the characteristics of the two populations were well 
balanced (supplementary table A).
Thirty day mortality was 2.3% in patients who received 
β blockers, compared with 8.6% in patients who did not 
(crude hazard ratio 0.26, 95% confidence interval 0.17 to 
0.38; P<0.001), and the difference  persisted after multi-
variable adjustment (hazard ratio 0.46, 0.26 to 0.82; 
P=0.008) (fig 2, panel A). In an analysis censoring 
patients who had died within 48 hours of admission, to 
avoid immortal time bias, early β blocker treatment was 
still associated with lower 30 day mortality (hazard ratio 
0.49, 0.26 to 0.92; P=0.026). Propensity score matched 
cohorts yielded similar results (hazard ratio 0.57, 0.36 to 
0.92; P=0.02) (supplementary fig A). Cause of death was 
cardiovascular in 89% of the patients, both for patients 
receiving and those not receiving β blockers.
Sensitivity analyses excluding patients who died in the 
first two days after admission showed consistent results 
(adjusted hazard ratio 0.62, 0.31 to 1.24; P=0.18). Like-
wise, we saw no interaction between the pre-specified 
subgroups (age, sex, type of acute myocardial infarction, 
left ventricular ejection fraction, use of percutaneous 
coronary intervention) and the association of early β 
blocker treatment with mortality (supplementary fig B), 
and no difference existed according to type of β blocker 
used (adjusted hazard ratio ranging from 0.41 to 0.54).
β blockers at discharge and one year mortality
In the 2217 patients discharged from hospital with no 
history of heart failure, no heart failure during the 
index admission, and left ventricular ejection fraction 
not 40% or less, 1783 (80.4%) were treated with β block-
ers at discharge (fig 1). As for early β blocker users, 
patients with β blockers at discharge were younger and 
had less comorbidity than those without (supplemen-
tary table B). After propensity score matching, the two 
groups of 383 patients with or without β blockers at dis-
charge were well balanced (supplementary table C).
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One year mortality was 3.4% in patients discharged 
taking β blockers compared with 7.8% in those without 
β blockers (crude hazard ratio 0.43, 0.28 to 0.65; 
P<0.001). After full adjustment, the hazard ratio was 
0.77 (0.46 to 1.30; P=0.32) (fig 2, panel B).
Likewise, in the propensity score matched cohorts, 
one year mortality was numerically lower in patients 
with β blockers at discharge (6.3% versus 7.3% in those 
without β blockers at discharge; hazard ratio 0.85, 0.50 
to 1.47; P=0.57). Death from cardiovascular disease at 
table 1 | Population 1: baseline characteristics according to early prescription (≤48 hours) of β blockers. values are 
numbers (percentages) unless stated otherwise
Without β blockers 
(n=629)
With β blockers 
(n=2050) P value
Demographics
Mean (SD) age, years 68.0 (13.6) 63.7 (13.6) <0.001
Age ≥75 years 232 (37) 497 (24) <0.001
Female sex 210 (33) 539 (26) 0.001
risk factors
Hypertension 374 (59) 1095 (53) 0.008
Hypercholesterolaemia 299 (48) 983 (48) 0.85
Current smoking 173 (28) 698 (34) 0.002
Diabetes mellitus 207 (33) 645 (31) 0.50
Family history of premature CVD 123 (20) 575 (28) <.001
Medical history
Previous stroke or TIA 54 (9) 114 (6) 0.006
Previous CABG 36 (6) 83 (4) 0.07
Previous PCI 94 (15) 245 (12) 0.05
Previous MI 108 (17) 280 (14) 0.03
Peripheral artery disease 67 (11) 113 (6) <0.001
Chronic kidney disease 26 (4) 69 (3) 0.36
Chronic obstructive lung disease 51 (8) 30 (1) <0.001
History of cancer 43 (7) 118 (6) 0.32
Drugs before index Mi
Antiplatelet agent 227 (36) 535 (26) <0.001
Statin 181 (29) 532 (26) 0.16
β blocker 81 (13) 520 (25) <0.001
ACE inhibitor 116 (18) 324 (16) 0.12
Angiotensin receptor blocker 110 (17) 281 (14) 0.02
index acute Mi
STEMI 335 (53) 1161 (57) 0.14
LBBB 23 (4) 34 (2) 0.002
Atrial fibrillation on admission electrocardiogram 40 (6) 92 (4.5) 0.06
Mean (SD) GRACE score 144 (29) 134 (28) <0.001
Median (IQR) maximal CK, IU/L 308 (146-934); (n=427) 544 (216-1441); (n=1749) <0.001
Median (IQR) LVEF, % 55 (48-65); (n=349) 55 (49-62); (n=1553) 0.67
Coronary angiography ≤48 hours of admission 412 (66) 1634 (80) <0.001
PCI in first 48 hours 249 (40) 1055 (51) <0.001
Reperfusion therapy in STEMI:
<0.001 Fibrinolysis 80 (24) 369 (32)
 Primary PCI 117 (35) 458 (39)
Coronary bypass graft during stay 22 (3) 88 (4) 0.38
LMWH in first 48 hours 354 (56) 1421 (69) <0.001
Clopidogrel in first 48 hours 490 (78) 1905 (93) <0.001
Statin in first 48 hours 372 (59) 1721 (84) <0.001
type of β blocker used
Acebutolol - 462 (23) -
Atenolol - 820 (40) -
Bisoprolol - 448 (22) -
Metoprolol - 208 (10) -
Other/unknown - 112 (5) -
Dose of β blocker prescribed at discharge (n=1973)
<50% of optimal - 416 (21) -
≥50% of optimal - 1339 (68) -
Dose unknown - 218 (11) -
ACE=angiotensin converting enzyme; CABG=coronary artery bypass grafting; CK=creatine kinase; CVD=cardiovascular disease; IQR=interquartile 
range; LBBB=left bundle branch block; LMWH=low molecular weight heparin; LVEF=left ventricular ejection fraction; MI=myocardial infarction; 
PCI=percutaneous coronary intervention; STEMI=ST elevation myocardial infarction; TIA= transient ischaemic attack.
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one year was significantly lower in patients receiving β 
blockers at discharge (2.6% versus 5.5% in those with-
out β blockers; P=0.044), but sudden cardiac death was 
similar (2.6% in each group). We found no difference in 
non-cardiovascular mortality (2.1% without versus 3.1% 
with β blockers at discharge).
Subgroup analyses according to age, sex, type of 
myocardial infarction, and left ventricular ejection 
 fraction (>50% and 40-50%) showed no significant 
interaction between β blockers at discharge and one 
year survival. Neither type of β blockers prescribed at 
discharge nor dose (28% taking moderate to high doses) 
was related to one year mortality after adjustment for 
age and GRACE score.
Continued β blocker treatment at one year and five 
year mortality
Among the 1783 patients with β blockers at discharge, 
1383 were alive at one year and had details of their pre-
scription available (population 3; fig 1 ). Of those, 153 
(11.1%) had stopped their β blockers. Most of the initial 
characteristics were similar between patients who dis-
continued β blockers and those who did not; however, 
other secondary prevention drugs at one year were less 
frequently used in patients who had stopped β blockers 
(table 2). After propensity score matching, the two 
cohorts (with or without β blockers at one year) were 
well matched (supplementary table D).
Five year mortality was 7.6% in patients still taking β 
blockers at one year, compared with 9.2% in those who 
were no longer taking β blockers at one year (crude haz-
ard ratio 0.79, 0.45 to 1.38; P=0.41). The adjusted hazard 
ratio was 1.19 (0.65 to 2.18; P=0.57) (fig 2, panel C). Cause 
of death was non-cardiovascular in a similar percent-
age of the patients with (45%) or without (35%) β block-
ers at one year. The adjusted hazard ratio for 
documented cardiovascular death was 0.90, and that 
for death of non-cardiovascular or unknown cause was 
0.99 (0.47 to 2.05). Sudden cardiac death was docu-
mented in 0.7% of the patients who had stopped β 
blockers, compared with 0.6% of those still taking β 
blockers at one year. The results were consistent across 
all subgroups (supplementary fig C), as well as in the 
propensity score matched cohorts (hazard ratio 1.10, 
0.41 to 2.97; P=0.85) (supplementary fig D). No heteroge-
neity existed according to type of β blocker used. Five 
year risk of death, recurrent myocardial infarction, or 
stroke was 13.7% in patients without and 10.9% in 
patients with persistent β blocker treatment at one year: 
crude hazard ratio 0.76 (0.48 to 1.21; P=0.25); adjusted 
hazard ratio 1.02 (0.62 to 1.09; P=0.94).
In the sensitivity analysis in three year survivors, 
according to persistence of β blocker treatment at three 
years, the hazard ratio for five year mortality was 1.32 
(0.51 to 3.37; P=0.51) for patients with continued treat-
ment, compared with those with permanent discontin-
uation at one and three years.
statin discontinuation after discharge and five year 
mortality
Among the 1256 patients who received statins and β 
blockers at hospital discharge, 136 (10.8%) had stopped 
statin treatment at one year. Five year mortality was 
5.8% in patients still taking statins at one year, com-
pared with 16.9% in those who had stopped (crude haz-
ard ratio 0.32, 0.20 to 0.51; P<0.001); the adjusted 
hazard ratio was 0.42 (0.25 to 0.72; P=0.001) (supple-
mentary fig E). Cause of death was non-cardiovascular 
in 56% of the patients without statins at one year, 
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Adjusted HR: 0.46 
(95% CI 0.26 to 0.82), P=0.008
Without β blockers
Adjusted HR: 0.77
(95% CI 0.46 to 1.30), P=0.32
Crude HR: 0.79
(95% CI 0.65 to 1.38), P=0.41
Adjusted HR: 1.19 
(95% CI 0.65 to 2.18), P=0.57
A
B
C
Fig 2 | survival according to β blocker use. a: 30 day 
survival according to β blocker use during first 48 hours 
after admission in patients with no history of heart failure 
and no heart failure on admission (population 1). b: one 
year survival according to β blocker prescription at 
discharge in patients with no history of heart failure and 
no documented left ventricular dysfunction (population 2). 
C: five year survival in patients discharged taking β 
blockers, according to continuation of β blocker treatment 
at one year (population 3). Hr=hazard ratio
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table 2 | Population 3: characteristics of patients discharged taking β blockers and alive at one year, according to 
discontinuation of β blockers in first year. values are numbers (percentages) unless stated otherwise
Without β blockers 
(n=153) With β blockers (n=1230) P value
Demographics
Mean (SD) age, years 64.7 (13.9) 63.0 (12.8) 0.12
Age ≥75 years 43 (28) 255 (21) 0.04
Female sex 46 (30) 327 (27) 0.36
risk factors
Hypertension 82 (54) 655 (53) 0.94
Hypercholesterolaemia 74 (48) 612 (50) 0.75
Current smoking 46 (30) 416 (34) 0.35
Diabetes mellitus 58 (38) 361 (29) 0.03
Medical history
Previous stroke or TIA 8 (5) 58 (5) 0.78
Previous CABG 8 (5) 46 (4) 0.37
Previous PCI 17 (11) 147 (12) 0.76
Previous MI 15 (10) 133 (11) 0.70
Peripheral artery disease 13 (9) 61 (5) 0.06
Chronic kidney disease 4 (3) 25 (2) 0.64
Chronic obstructive lung disease 3 (2) 14 (1) 0.38
History of cancer 5 (3) 60 (5) 0.37
Drugs before index acute Mi
Antiplatelet agent 32 (21) 300 (24) 0.34
Statin 38 (25) 330 (27) 0.60
β blocker 33 (22) 310 (25) 0.33
ACE inhibitor 24 (16) 173 (14) 0.59
Angiotensin receptor blocker 27 (18) 197 (16) 0.61
index acute Mi
STEMI 80 (52) 700 (57) 0.28
Atrial fibrillation on first electrocardiogram 5 (3) 40 (3) 0.99
Mean (SD) GRACE score, 6 months 106 (29) 101 (26) 0.07
Mean (SD) GRACE score 2.0, simplified 3 years 0.86 (0.15) 0.88 (0.12) 0.008
Median (IQR) maximal CK, IU/L 428 (190-1078); (n=129) 520 (203 to 1340); (n=1089) 0.108
Median (IQR) LVEF, % 60 (50-65); (n=112) 57 (50-64); (n=949) 0.238
Coronary angiography 143 (93) 1194 (97) 0.02
Reperfusion therapy in STEMI:
0.793 Fibrinolysis 28 (35) 222 (32)
 Primary PCI 29 (36) 278 (40)
PCI 114 (75) 960 (78) 0.32
PCI in first 48 hours 75 (49) 659 (54) 0.29
Multivessel CAD 54 (35) 520 (42) 0.19
LMWH in first 48 hours 116 (76) 872 (71) 0.20
Clopidogrel in first 48 hours 142 (93) 1158 (94) 0.51
β blocker in first 48 hours 131 (86) 1091 (89) 0.26
LVEF >50% 81/112 (72) 662/950 (70) 0.56
Recurrent MI 1 (1) 16 (1) 0.49
Stroke 1 (1) 3 (0.2) 0.37
Major bleeding 4 (3) 12 (1) 0.07
Ventricular fibrillation 0 (0) 14 (1) 0.18
recurrent acute Mi or stroke
During first year 6 (4) 41 (3) 0.70
Drugs at 1 year
Statin 99 (65) 1094 (89) <0.001
Aspirin 107 (70) 1094 (89) <0.001
Clopidogrel 90 (59) 964 (78) <0.001
ACE inhibitor 74 (48) 747 (61) 0.003
Angiotensin receptor blocker 18 (12) 180 (15) 0.34
type of β blocker at 1 year
Acebutolol - 270 (22) -
Atenolol - 401 (33) -
Bisoprolol - 361 (29) -
Metoprolol - 91 (7) -
Other/unknown - 107 (9) -
ACE=angiotensin converting enzyme; CABG=coronary artery bypass grafting; CAD=coronary artery disease; CK=creatine kinase; IQR=interquartile 
range; LBBB=left bundle branch block; LMWH=low molecular weight heparin; LVEF=left ventricular ejection fraction; MI=myocardial infarction; 
PCI=percutaneous coronary intervention; STEMI=ST elevation myocardial infarction; TIA=transient ischaemic attack.
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 compared with 36% of those taking statins at one year. 
Propensity score matched cohorts showed consistent 
results (supplementary fig F). Five year risk of death, 
recurrent myocardial infarction, or stroke was 21.3% in 
those who had stopped statins at one year versus 10.4% 
in those with continued statin treatment: crude hazard 
ratio 0.46 (0.31 to 0.68; P<0.001); adjusted hazard ratio 
0.57 (0.37 to 0.88; P=0.01).
discussion
The main findings of our study are that early use of β 
blocker treatment is related to a substantial reduction 
in risk of 30 day mortality in patients with acute myo-
cardial infarction without heart failure, whereas its use 
at discharge is associated with a non-significant reduc-
tion in one year mortality. Stopping β blocker treatment 
in the year after the acute myocardial infarction was not 
related to a higher risk of mortality up to five years, in 
contrast with the increased five year mortality observed 
in those patients who stopped statin treatment. No 
 heterogeneity existed across subgroups, and the data 
were consistent whatever the type and dose of β blocker 
used. These observations suggest a progressively 
decreasing benefit of β blocker treatment over time.
initial randomised trials and their effect on 
guidelines
Most of the evidence on β blockers in patients with 
acute myocardial infarction dates back to the pre-reper-
fusion era; β blockers reduced mortality both acutely 
and in the long term.3  This has been the basis for a high 
level of recommendations in both European and Amer-
ican guidelines.12 13  Recently, however, European guide-
lines, taking into account the fact that evidence on the 
usefulness of β blockers in the contemporary era was 
lacking, have downgraded the level of recommendation 
from class I to IIa,8  whereas the American guidelines 
still give the highest level of recommendation for β 
blockers, both in ST elevation myocardial infarction 
and non-ST elevation acute coronary syndromes.6 7
The most recent meta-analysis of β blockers in acute 
myocardial infarction found that these agents reduced 
mortality before the reperfusion era, whereas this was no 
longer the case in the reperfusion era.9  Data in the reper-
fusion era, however, mostly rely on the results of the large 
COMMIT trial,4 in which metoprolol (intravenous fol-
lowed by oral administration) had no effect on mortality 
but reduced the risk of recurrent myocardial infarction at 
28 days, in a population in whom primary percutaneous 
coronary intervention was not used and fibrinolysis was 
administered in only 55%; of note, and in keeping with 
our results, early β blocker treatment was associated with 
numerically lower 28 day mortality in patients who were 
Killip class I at entry. Overall, however, very little informa-
tion on the effects of β blockers beyond the first month in 
the reperfusion era is available from randomised trials.
Comparison with other observational studies
Most recent information comes from observational 
cohorts. Twenty years ago, the Cooperative Cardiovascu-
lar project found that one third of more than 200 000 
Medicare patients with acute myocardial infarction, of 
whom only a minority had reperfusion therapy, were dis-
charged taking β blockers; prescription of β blockers at 
discharge was associated with improved survival at 24 
months, particularly in high risk groups, and to a greater 
extent in the case of non-transmural infarction.14  Other 
registries, such as GRACE in non-ST elevation myocardial 
infarction patients or the Korean registry in patients with 
primary percutaneous coronary intervention, showed 
that β blocker prescription at discharge was associated 
with lower mortality at six months (GRACE) and up to 
three years (Korean  registry).15 16  In the Prospective Regis-
try Evaluating Myocardial Infarction: Event and Recovery 
(PREMIER) registry,17  early discontinuation of β blockers 
(one month after acute myocardial infarction) was associ-
ated with a twofold increase in mortality at one year. In 
the Ontario reimbursement database,18  poor adherence 
to β blockers (<40% of days covered) in the year after 
acute myocardial infarction in older patients was associ-
ated with increased mortality (hazard ratio 1.13, 95% con-
fidence interval 1.03 to 1.25). A similar trend was observed 
in the Reduction of Atherothrombosis for Continued 
Health (REACH) registry,19  for patients with a myocardial 
infarction within one year of inclusion (hazard ratio for 
cardiovascular death, myocardial infarction, or stroke 
0.79 (0.60 to 1.04) in patients receiving β blockers). Thus, 
the data from our study on one year mortality according 
to prescription of β blockers at discharge seem to be con-
sistent with previous findings suggesting the beneficial 
effect of early β blocker treatment on survival in the first 
months after the acute episode, even in contemporary 
populations with high rates of primary percutaneous cor-
onary intervention. Recently, the Outcomes of β-blocker 
Therapy After Myocardial Infarction (OBTAIN) registry 
studied the association between dose of β blocker and 
two year survival in 6682 patients discharged after an ST 
elevation or non-ST elevation myocardial infarction.20 
Mortality was lower in patients discharged taking β block-
ers but was not significantly related to β blocker dose.
Data on the role of β blocker treatment after the first 
months following acute myocardial infarction are even 
more limited and suggest that it has less (if any) effect 
on major cardiovascular outcomes. In the REACH 
 registry,19  the risk of cardiovascular death, myocardial 
infarction, or stroke at 44 months associated with β 
blocker use did not differ either in the whole cohort of 
patients with previous myocardial infarction (hazard 
ratio 0.90, 0.79 to 1.03) or among those with coronary 
artery disease and no history of myocardial infarction 
(0.92, 0.79 to 1.08). In both groups, the risk of death was 
slightly, and not significantly, reduced in patients 
treated with β blockers, whereas the risk of myocardial 
infarction was slightly increased. Specific results in 
patients with a history of acute myocardial infarction 
more than one year before inclusion were not reported. 
Likewise, in the Kaiser Permanente database analysis of 
patients with newly diagnosed coronary artery disease 
(acute coronary syndrome or myocardial revascularisa-
tion),21 mortality was significantly higher when the 
patients were not taking β blockers, compared with tak-
ing β blockers, but with a strong interaction with the 
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presence of recent myocardial infarction. β blockers 
were significantly associated with decreased mortality 
in patients with a recent myocardial infarction (hazard 
ratio 0.85, 0.79 to 0.92), but no increase in mortality was 
seen in patients with either an older history of myocar-
dial infarction or no myocardial infarction (hazard ratio 
1.02, 0.91 to 1.15). Again, specific results in patients with 
an acute myocardial infarction more than one year pre-
viously were not reported.
Finally, when we analysed the outcomes of patients 
with a history of heart failure or low ejection fraction 
(that is, those not included in the main analysis) who 
had stopped β blockers during the first year, we found 
results concordant with what would be expected from 
the results of randomised trials in patients with heart 
failure/low ejection fraction, with a strong association 
with a higher five year mortality (adjusted hazard ratio 
2.11, 1.16 to 3.83; P=0.014).
limitations of study
As in all observational studies, this analysis has lim-
itations. At the acute stage, the most severely ill 
patients less often receive β blockers, and statistical 
techniques may not be sufficient to adjust completely 
for these confounders, thereby increasing the mea-
sured favourable association between early β blocker 
treatment and mortality. Conversely, because only a 
minority of patients did not receive β blockers at dis-
charge and a smaller minority still discontinued β 
blockers during the first year, we cannot exclude the 
possibility that unusual, and therefore unmeasured, 
confounders explaining the absence of prescription or 
discontinuation of treatment existed. However, 
FAST-MI provided very detailed characterisation of the 
patients, making it unlikely that major confounders 
were not recorded. In addition, unrecorded confound-
ers would probably have been similar for statins and β 
blockers.
Also, we did not do a formal sample size calculation 
for our analysis, and the limited size of our population 
increases the risk of a type B error and of an underesti-
mation of the potential benefit of β blockers, especially 
during the first year. Therefore, the lack of statistical 
significance for β blocker prescription at discharge can-
not be considered proof of its lack of effect. Likewise, 
subgroup analyses or analyses according to type or 
dose of β blockers should be interpreted with caution.
More importantly, most observational data have 
shown that patients who adhere to preventive drugs are 
more “health conscious” than those who do not 
adhere,22-24 with a less severe profile, including their 
socioeconomic status, and an overall better prognosis, 
thus leading to a “healthy user” bias (in other words, 
adherence to any drug in itself is associated with higher 
survival). In this regard, the striking difference between 
mortality in patients who stopped β blockers and those 
who stopped statins (granting that patients stopping β 
blockers were also more likely to stop other recom-
mended drugs such as statins) suggests that the lack of 
prognostic significance of β blocker discontinuation at 
one year is unlikely to have been affected by such a bias.
Conclusions
The results presented suggest a decrease over time in 
the effect of β blocker treatment on survival in patients 
with acute myocardial infarction without heart failure 
or left ventricular dysfunction. Early use of β blockers at 
the acute stage of myocardial infarction was associated 
with a substantial decrease in 30 day mortality, whereas 
prolonged β blocker treatment beyond one year is 
unlikely to improve survival.
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